Information on EC 1.1.1.146 - 11beta-hydroxysteroid dehydrogenase

New: Word Map on EC 1.1.1.146
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
Specify your search results
Mark a special word or phrase in this record:
Search Reference ID:
Select one or more organisms in this record:
Show additional data
Do not include text mining results
Include (text mining) results (more...)
Include results (AMENDA + additional results, but less precise; more...)


The expected taxonomic range for this enzyme is: Eukaryota, Bacteria

EC NUMBER
COMMENTARY hide
1.1.1.146
-
RECOMMENDED NAME
GeneOntology No.
11beta-hydroxysteroid dehydrogenase
REACTION
REACTION DIAGRAM
COMMENTARY hide
ORGANISM
UNIPROT
LITERATURE
an 11beta-hydroxysteroid + NADP+ = an 11-oxosteroid + NADPH + H+
show the reaction diagram
REACTION TYPE
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
oxidation
-
-
-
-
redox reaction
-
-
-
-
reduction
-
-
-
-
PATHWAY
BRENDA Link
KEGG Link
MetaCyc Link
Metabolic pathways
-
-
Metabolism of xenobiotics by cytochrome P450
-
-
Steroid hormone biosynthesis
-
-
SYSTEMATIC NAME
IUBMB Comments
11beta-hydroxysteroid:NADP+ 11-oxidoreductase
-
CAS REGISTRY NUMBER
COMMENTARY hide
9041-46-7
-
ORGANISM
COMMENTARY hide
LITERATURE
UNIPROT
SEQUENCE DB
SOURCE
-
-
-
Manually annotated by BRENDA team
-
-
-
Manually annotated by BRENDA team
-
-
-
Manually annotated by BRENDA team
isoenzymes type 1 and type 2
-
-
Manually annotated by BRENDA team
dogfish
-
-
-
Manually annotated by BRENDA team
-
-
-
Manually annotated by BRENDA team
; type 1 enzyme
-
-
Manually annotated by BRENDA team
-
-
-
Manually annotated by BRENDA team
-
SwissProt
Manually annotated by BRENDA team
no activity in frog
no activity for the oxidative direction in frog, toad, mud, puppy, shark and bird livers
-
-
Manually annotated by BRENDA team
no activity in Necturus maculosus
-
-
-
Manually annotated by BRENDA team
no activity in shark
-
-
-
Manually annotated by BRENDA team
no activity in toad
no activity for the oxidative direction in frog, toad, mud, puppy, shark and bird livers
-
-
Manually annotated by BRENDA team
-
-
-
Manually annotated by BRENDA team
GENERAL INFORMATION
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
physiological function
-
the two reactions 11beta-HSD1-dehydrogenase, EC 1.1.1146, and 17beta-HSD3, EC 1.1.1.64, which utilize NADPH are competing for NADPH from the same cofactor pool. 11beta-HSD1-dehydrogenase serves as a NADPH-regenerating system that is tightly coupled in regulating 17beta-HSD3 reaction synthesizing testosterone. A cycle can exist whereby the NADPH produced by 11beta-HSD1 dehydrogenase can drive the reductase activity of 17beta-HSD3 and the NADP+ produced by 17beta-HSD3 and other enzymes involved in testosterone biosynthesis can drive the dehydrogenase activity of 11beta-HSD1
SUBSTRATE
PRODUCT                       
REACTION DIAGRAM
ORGANISM
UNIPROT
COMMENTARY
(Substrate) hide
LITERATURE
(Substrate)
COMMENTARY
(Product) hide
LITERATURE
(Product)
Reversibility
r=reversible
ir=irreversible
?=not specified
1,2-dehydrocortisol + NADP+
1,2-dehydrocortisone + NADPH
show the reaction diagram
-
-
-
-
r
1,2-dehydrocortisone + NADPH
1,2-dehydrocortisol + NADP+
show the reaction diagram
11-dehydrocorticosterone + NADPH
corticosterone + NADP+
show the reaction diagram
11-dehydrocorticosterone + NADPH + H+
corticosterone + NADP+
show the reaction diagram
11-oxo-progesterone + NADPH + H+
11beta-hydroxyprogesterone + NADP+
show the reaction diagram
11alpha-hydroxy-pregn-4-ene-3,20-dione + ?
pregn-4-ene-3,11,20-trione + ?
show the reaction diagram
11beta,17,21-trihydroxy-pregn-4-ene-3,20-dione + ?
17,21-dihydroxy-pregn-4-ene-3,11,20-trione + ?
show the reaction diagram
-
i.e. cortisol
-
?
11beta,17,21-trihydroxy-pregn-4-ene-3,20-dione + NADP+
17,21-dihydroxy-pregn-4-ene-3,11,20-trione + NADPH
show the reaction diagram
11beta,17beta-dihydroxyandrost-4-ene-3-one + ?
17beta-hydroxyandrost-4-ene-3,11-dione + ?
show the reaction diagram
11beta,20alpha-dihydroxypregn-4-ene-3-one + ?
20alpha-hydroxypregn-4-ene-3,11-dione + ?
show the reaction diagram
11beta,20beta-dihydroxypregn-4-ene-3-one + ?
20beta-hydroxypregn-4-ene-3,11-dione + ?
show the reaction diagram
11beta,21-dihydroxypregn-4-en-3,20-dione + ?
11-dehydro,21-hydroxy-pregn-4-en-3,20-dione + ?
show the reaction diagram
11beta,21-dihydroxypregn-4-en-3,20-dione + NAD+
21-hydroxy-pregn-4-en-3,11,20-trione + NADH + H+
show the reaction diagram
11beta,21-dihydroxypregn-4-en-3,20-dione + NADP+
21-hydroxy-pregn-4-en-3,11,20-trione + NADPH
show the reaction diagram
11beta,21-dihydroxypregn-4-en-3,20-dione + NADP+
21-hydroxy-pregn-4-en-3,11,20-trione + NADPH + H+
show the reaction diagram
11beta-hydroxy-pregn-4-ene-3,20-dione + ?
pregn-4-ene-3,11,20-trione + ?
show the reaction diagram
11beta-hydroxyandrost-4-ene-3,17-dione + ?
androst-4-ene-3,11,17-trione + ?
show the reaction diagram
11beta-hydroxytestosterone + NAD+
11-oxotestosterone + NADH + H+
show the reaction diagram
-
-
-
-
?
12alpha-fluoro-11-dehydrocorticosterone + NADPH
12alpha-fluoro-corticosterone + NADP+
show the reaction diagram
-
-
-
ir
15-deoxy-D12,14-prostaglandin J2 + NADPH
?
show the reaction diagram
-
isozyme 11beta-HSD1
-
-
?
16alpha-methyl-1,2-dehydrocortisone + NADPH
16alpha-methyl-1,2-dehydrocortisol + NADP+
show the reaction diagram
16alpha-methylcortisol + NADP+
16alpha-methylcortisone + NADPH
show the reaction diagram
-
-
-
-
16alpha-methylcortisone + NADPH
16alpha-methylcortisol + NADP+
show the reaction diagram
16beta-methylcortisol + NADP+
16beta-methylcortisone + NADPH
show the reaction diagram
-
-
-
-
17,21-dihydroxy-pregn-4-ene-3,11,20-trione + NADPH
11beta,17,21-trihydroxy-pregn-4-ene-3,20-dione + NADP+
show the reaction diagram
17alpha,21-dihydroxypregna-1,4-diene-3,11,20-trione + NADPH
11beta,17alpha,21-trihydroxypregna-1,4-diene-3,20-dione + NADP+
show the reaction diagram
-
i.e. prednisone
i.e. prednisolone
?
2,3-benzoylphenyl-propanoic acid + NADPH
2,3-benzoylphenyl-propanol + NADP+
show the reaction diagram
20alpha-hydroxypregn-4-ene-3-one + ?
20alpha-hydroxypregn-4-ene-3,11-dione + ?
show the reaction diagram
21-hydroxy-pregn-4-en-3,11,20-trione + NADPH
11beta,21-dihydroxypregn-4-en-3,20-dione + NADP+
show the reaction diagram
4-methylnitrosamine-1-(3-pyridiyl)-1-butanone + NADPH
4-methylnitrosamine-1-(3-pyridiyl)-1-butanol + NADP+
show the reaction diagram
-
-
-
-
?
4-methylnitrosamino-1-(3-pyridyl)-1-butanone + NADPH
4-methylnitrosamino-1-(3-pyridyl)-1-butanol + NADP+
show the reaction diagram
-
i.e. NNK, genotoxic compound from tobacco smoke, isozyme 11beta-HSD1, carbonyl reductase activity, EC 1.1.1.184
-
-
r
5,5-dimethyl-3-(3-fluorphenyl)-4-(4-methylsulfonyl)phenyl-2-(5H-furanone)-lactol + NADP+
5,5-dimethyl-3-(3-fluorphenyl)-4-(4-methylsulfonyl)phenyl-2-(5H-furanone)-lactone + NADPH
show the reaction diagram
5alpha-androstane-3beta,7alpha,17beta-triol + NADP+
5alpha-androstane-3beta,7beta,17beta-triol + NADPH
show the reaction diagram
-
interconversion of 7alpha to 7beta isoform, ratio Vmax/Km is 2 pmol min-1 microgramm-1/microMol
-
-
r
5alpha-androstane-3beta,7beta,17beta-triol + NADP+
5alpha-androstane-3beta,7alpha,17beta-triol + NADP
show the reaction diagram
-
interconversion of 7beta to 7alpha isoform, ratio Vmax/Km is 0.5 pmol min-1 microgramm-1/microMol
-
-
r
6-[2-(2-hydroxy-ethylamino)-ethyl]-6H-indeno[1,2-c]isoquinoline-5,11-dione + NADPH
(+)-6-[2-(2-hydroxyethyl)aminoethyl]-5-oxo-11-hydroxy-5,6-dihydro-11H-indeno[1,2-c]isoquinoline + NADP+
show the reaction diagram
-
trivial name oracin, cytostatic drug, 11beta-HSD 1 exhibits enzyme cooperativity for the formation of both hydroxy-enantiomers
24% (+)-stereoisomer
-
?
6-[2-(2-hydroxy-ethylamino)-ethyl]-6H-indeno[1,2-c]isoquinoline-5,11-dione + NADPH + H+
(-)-6-[2-(2-hydroxyethyl)aminoethyl]-5-oxo-11-hydroxy-5,6-dihydro-11H-indeno[1,2-c]isoquinoline + NADP+
show the reaction diagram
-
trivial name oracin, cytostatic drug
76% (-)-stereoisomer
-
?
7-ketodehydroepiandrosterone + 2 NADPH + 2 H+
7alpha-hydroxydehydroepiandrosterone + 7beta-hydroxydehydroepiandrosterone + 2 NADP+
show the reaction diagram
-
-
formation of alpha- and beta-product in almost equal amounts. In presence of hexose-6-phosphate dehydrogenase, the 7keto-substrate is almost fully metabolized and the 7beta-product is preferentially formed
-
?
7-oxo-5alpha-androstane-3beta,17beta-diol + NADPH
5alpha-androstane-3beta,7alpha,17beta-triol + 5alpha-androstane-3beta,7alpha,17beta-triol + NADP+
show the reaction diagram
-
-
-
-
r
7-oxocholesterol + NADPH
7beta-hydroxycholesterol + 7alpha-hydroxycholesterol + NADPH
show the reaction diagram
-
40% and 60%, respectively, in lysates of HEK-293 cells and intact HEK-293 cells expressing 11beta-HSD1
-
r
7-oxocholesterol + NADPH
7beta-hydroxycholesterol + NADP+
show the reaction diagram
7alpha-hydroxycholesterol + NADP+
7-oxocholesterol + NADPH
show the reaction diagram
in lysates of HEK-293 cells expressing 11beta-HSD1, no oxidation in intact HEK293 cells expressing 11beta-HSD1
-
-
r
7alpha-hydroxydehydroepiandrosterone + NADP+
7beta-hydroxydehydroepiandrosterone + 7-ketodehydroepiandrosterone + NADPH
show the reaction diagram
-
-
in presence of hexose-6-phosphate dehydrogenase, less substrate is metabolized and accumulation of 7-ketodehydroepiandrosterone is abolished
-
?
7beta-hydroxycholesterol + NADP+
7-oxocholesterol + NADPH
show the reaction diagram
7beta-hydroxydehydroepiandrosterone + NADP+
7alpha-hydroxydehydroepiandrosterone + 7-ketodehydroepiandrosterone + NADPH
show the reaction diagram
-
-
formation of products in almost equal amounts. In presence of hexose-6-phosphate dehydrogenase, less substrate is metabolized and accumulation of 7-ketodehydroepiandrosterone is abolished
-
?
9alpha-fluoro-11-oxoprogesterone + NADPH
9alpha-fluoro-11beta-hydroxyprogesterone + NADP+
show the reaction diagram
-
-
-
ir
9alpha-fluorocortisone + NADPH
9alpha-fluorocortisol + NADP+
show the reaction diagram
androst-4-ene-3,11,17-trione + NADPH
11beta-hydroxyandrost-4-ene-3,17-dione + NADP+
show the reaction diagram
androst-4-ene-3,11,17-trione + NADPH
11beta-hydroxyandrost-4-ene-3,17-one + NADP+
show the reaction diagram
androstenedione + NADPH + H+
testosterone + NADP+
show the reaction diagram
corticosterone + NADP+
11-dehydrocorticosterone + NADPH
show the reaction diagram
corticosterone + NADP+
11-dehydrocorticosterone + NADPH + H+
show the reaction diagram
corticosterone + NADP+
?
show the reaction diagram
-
-
-
-
?
corticosterone + NADPH
corticosterol + NADP+
show the reaction diagram
-
-
-
-
r
corticosterone + NADPH + H+
corticosterol + NADP+
show the reaction diagram
cortisol + NAD+
cortisone + NADH
show the reaction diagram
cortisol + NAD+
cortisone + NADH + H+
show the reaction diagram
cortisol + NADP+
cortisone + NADPH
show the reaction diagram
cortisone + NAD(P)H
cortisol + NAD(P)+
show the reaction diagram
cortisone + NADPH
cortisol + NADP+
show the reaction diagram
cortisone + NADPH
cortisol + NADP+ + H+
show the reaction diagram
cortisone + NADPH
cortisole + NADP+
show the reaction diagram
-
-
-
-
?
cortisone + NADPH + H+
cortisol + NADP+
show the reaction diagram
dehydrocorticosterone + NADPH
corticosterone + NADP+
show the reaction diagram
dexamethasone + NADP+
11-dehydromethasone + NADPH
show the reaction diagram
metyrapone + NADPH
? + NADP+
show the reaction diagram
-
-
-
r
oracin + NADPH + H+
11-dihydrooracin + NADP+
show the reaction diagram
oracin + NADPH + H+
dihydrooracin + NADP+
show the reaction diagram
-
a cytostatic drug, isozyme 11beta-HSD1, carbonyl reductase activity, EC 1.1.1.184, stereochemical ratio of 3:1 for R:S enantiomers of the pro-chiral carbonyl centre of oracin, inactivation of the anti-cancer drug
-
-
r
pregn-4-ene-3,11,20-trione + NADPH
11beta-hydroxy-pregn-4-ene-3,20-dione + NADP+
show the reaction diagram
additional information
?
-
NATURAL SUBSTRATES
NATURAL PRODUCTS
REACTION DIAGRAM
ORGANISM
UNIPROT
COMMENTARY
(Substrate) hide
LITERATURE
(Substrate)
COMMENTARY
(Product) hide
LITERATURE
(Product)
REVERSIBILITY
r=reversible
ir=irreversible
?=not specified
1,2-dehydrocortisol + NADP+
1,2-dehydrocortisone + NADPH
show the reaction diagram
-
-
-
-
r
11-dehydrocorticosterone + NADPH
corticosterone + NADP+
show the reaction diagram
11alpha-hydroxy-pregn-4-ene-3,20-dione + ?
pregn-4-ene-3,11,20-trione + ?
show the reaction diagram
11beta,17,21-trihydroxy-pregn-4-ene-3,20-dione + ?
17,21-dihydroxy-pregn-4-ene-3,11,20-trione + ?
show the reaction diagram
-
i.e. cortisol
-
?
11beta,17,21-trihydroxy-pregn-4-ene-3,20-dione + NADP+
17,21-dihydroxy-pregn-4-ene-3,11,20-trione + NADPH
show the reaction diagram
11beta,17beta-dihydroxyandrost-4-ene-3-one + ?
17beta-hydroxyandrost-4-ene-3,11-dione + ?
show the reaction diagram
11beta,20alpha-dihydroxypregn-4-ene-3-one + ?
20alpha-hydroxypregn-4-ene-3,11-dione + ?
show the reaction diagram
11beta,20beta-dihydroxypregn-4-ene-3-one + ?
20beta-hydroxypregn-4-ene-3,11-dione + ?
show the reaction diagram
11beta,21-dihydroxypregn-4-en-3,20-dione + ?
11-dehydro,21-hydroxy-pregn-4-en-3,20-dione + ?
show the reaction diagram
11beta,21-dihydroxypregn-4-en-3,20-dione + NAD+
21-hydroxy-pregn-4-en-3,11,20-trione + NADH + H+
show the reaction diagram
11beta,21-dihydroxypregn-4-en-3,20-dione + NADP+
21-hydroxy-pregn-4-en-3,11,20-trione + NADPH
show the reaction diagram
11beta,21-dihydroxypregn-4-en-3,20-dione + NADP+
21-hydroxy-pregn-4-en-3,11,20-trione + NADPH + H+
show the reaction diagram
11beta-hydroxy-pregn-4-ene-3,20-dione + ?
pregn-4-ene-3,11,20-trione + ?
show the reaction diagram
11beta-hydroxyandrost-4-ene-3,17-dione + ?
androst-4-ene-3,11,17-trione + ?
show the reaction diagram
11beta-hydroxytestosterone + NAD+
11-oxotestosterone + NADH + H+
show the reaction diagram
-
-
-
-
?
17,21-dihydroxy-pregn-4-ene-3,11,20-trione + NADPH
11beta,17,21-trihydroxy-pregn-4-ene-3,20-dione + NADP+
show the reaction diagram
17alpha,21-dihydroxypregna-1,4-diene-3,11,20-trione + NADPH
11beta,17alpha,21-trihydroxypregna-1,4-diene-3,20-dione + NADP+
show the reaction diagram
-
i.e. prednisone
i.e. prednisolone
?
21-hydroxy-pregn-4-en-3,11,20-trione + NADPH
11beta,21-dihydroxypregn-4-en-3,20-dione + NADP+
show the reaction diagram
4-methylnitrosamino-1-(3-pyridyl)-1-butanone + NADPH
4-methylnitrosamino-1-(3-pyridyl)-1-butanol + NADP+
show the reaction diagram
-
i.e. NNK, genotoxic compound from tobacco smoke, isozyme 11beta-HSD1, carbonyl reductase activity, EC 1.1.1.184
-
-
r
7beta-hydroxycholesterol + NADP+
7-oxocholesterol + NADPH
show the reaction diagram
androst-4-ene-3,11,17-trione + NADPH
11beta-hydroxyandrost-4-ene-3,17-one + NADP+
show the reaction diagram
androstenedione + NADPH + H+
testosterone + NADP+
show the reaction diagram
-
the two reactions 11beta-HSD1-dehydrogenase, EC 1.1.1146, and 17beta-HSD3, EC 1.1.1.64, which utilize NADPH are competing for NADPH from the same cofactor pool. 11beta-HSD1-dehydrogenase serves as a NADPH-regenerating system that is tightly coupled in regulating 17beta-HSD3 reaction synthesizing testosterone. A cycle can exist whereby the NADPH produced by 11beta-HSD1 dehydrogenase can drive the reductase activity of 17beta-HSD3 and the NADP+ produced by 17beta-HSD3 and other enzymes involved in testosterone biosynthesis can drive the dehydrogenase activity of 11beta-HSD1
i.e. 4-androsten-17beta-ol-3-one
-
?
corticosterone + NADP+
11-dehydrocorticosterone + NADPH
show the reaction diagram
corticosterone + NADP+
11-dehydrocorticosterone + NADPH + H+
show the reaction diagram
-
bidirectional in vitro, believed to predominantly function as an oxidoreductase in vivo
-
-
r
cortisol + NAD+
cortisone + NADH
show the reaction diagram
P50172, P51661
isozyme 11beta-HSD2 catalyzes the reverse reaction with cofactor NAD+
-
-
ir
cortisol + NADP+
cortisone + NADPH
show the reaction diagram
cortisone + NAD(P)H
cortisol + NAD(P)+
show the reaction diagram
cortisone + NADPH
cortisol + NADP+
show the reaction diagram
cortisone + NADPH
cortisol + NADP+ + H+
show the reaction diagram
cortisone + NADPH
cortisole + NADP+
show the reaction diagram
-
-
-
-
?
dehydrocorticosterone + NADPH
corticosterone + NADP+
show the reaction diagram
-
isozyme 11beta-HSD1, 11beta-hydroxysteroid dehydrogenase activity, EC 1.1.1.146
-
-
r
oracin + NADPH + H+
dihydrooracin + NADP+
show the reaction diagram
-
a cytostatic drug, isozyme 11beta-HSD1, carbonyl reductase activity, EC 1.1.1.184, stereochemical ratio of 3:1 for R:S enantiomers of the pro-chiral carbonyl centre of oracin, inactivation of the anti-cancer drug
-
-
r
pregn-4-ene-3,11,20-trione + NADPH
11beta-hydroxy-pregn-4-ene-3,20-dione + NADP+
show the reaction diagram
additional information
?
-
COFACTOR
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
METALS and IONS
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
additional information
INHIBITORS
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
(+/-)-2-((cyclohexylmethyl)amino)-5-ethyl-5-methyl-1,3-thiazol-4-(5H)-one
-
inhibitor for isozyme 11beta-HSD1, but not for isozyme 11beta-HSD2
(+/-)-2-((cyclohexylmethyl)amino)-5-methyl-5-propyl-1,3-thiazol-4-(5H)-one
-
inhibitor for isozyme 11beta-HSD1, but not for isozyme 11beta-HSD2
(+/-)-2-(1-adamantylamino)-5-ethyl-5-methyl-1,3-thiazol-4-(5H)-one
-
inhibitor for isozyme 11beta-HSD1, but not for isozyme 11beta-HSD2
(+/-)-2-(1-adamantylamino)-5-methyl-5-propyl-1,3-thiazol-4-(5H)-one
-
inhibitor for isozyme 11beta-HSD1, but not for isozyme 11beta-HSD2
(+/-)-2-(cycloheptylamino)-5-ethyl-5-methyl-1,3-thiazol-4-(5H)-one
-
inhibitor for isozyme 11beta-HSD1, but not for isozyme 11beta-HSD2
(+/-)-2-(cycloheptylamino)-5-methyl-5-propyl-1,3-thiazol-4-(5H)-one
-
inhibitor for isozyme 11beta-HSD1, but not for isozyme 11beta-HSD2
(+/-)-2-(cyclohexylamino)-5-ethyl-5-methyl-1,3-thiazol-4-(5H)-one
-
inhibitor for isozyme 11beta-HSD1, but not for isozyme 11beta-HSD2
(+/-)-2-(cyclohexylamino)-5-methyl-5-propyl-1,3-thiazol-4-(5H)-one
-
inhibitor for isozyme 11beta-HSD1, but not for isozyme 11beta-HSD2
(+/-)-2-(cyclooctylamino)-5-ethyl-5-methyl-1,3-thiazol-4-(5H)-one
-
inhibitor for isozyme 11beta-HSD1, but not for isozyme 11beta-HSD2
(+/-)-2-(cyclooctylamino)-5-methyl-5-propyl-1,3-thiazol-4-(5H)-one
-
inhibitor for isozyme 11beta-HSD1, but not for isozyme 11beta-HSD2
(+/-)-5-ethyl-5-methyl-2-(1-norbornylamino)-1,3-thiazol-4-(5H)-one
-
inhibitor for isozyme 11beta-HSD1, but not for isozyme 11beta-HSD2
(+/-)-5-ethyl-5-methyl-2-(3-noradamantylamino)-1,3-thiazol-4-(5H)-one
-
inhibitor for isozyme 11beta-HSD1, but not for isozyme 11beta-HSD2
(+/-)-5-ethyl-5-methyl-2-(7-norbornylamino)-1,3-thiazol-4-(5H)-one
-
inhibitor for isozyme 11beta-HSD1, but not for isozyme 11beta-HSD2
(+/-)-5-ethyl-5-methyl-2-[(2,2,3,3-tetramethylcyclopropyl)amino]-1,3-thiazol-4-(5H)-one
-
inhibitor for isozyme 11beta-HSD1, but not for isozyme 11beta-HSD2
(+/-)-5-methyl-2-(1-norbornylamino)-5-propyl-1,3-thiazol-4-(5H)-one
-
inhibitor for isozyme 11beta-HSD1, but not for isozyme 11beta-HSD2
(+/-)-5-methyl-2-(3-noradamantylamino)-5-propyl-1,3-thiazol-4-(5H)-one
-
inhibitor for isozyme 11beta-HSD1, but not for isozyme 11beta-HSD2
(+/-)-5-methyl-2-(7-norbornylamino)-5-propyl-1,3-thiazol-4-(5H)-one
-
inhibitor for isozyme 11beta-HSD1, but not for isozyme 11beta-HSD2
(+/-)-5-methyl-5-propyl-2-[(2,2,3,3-tetramethylcyclopropyl)amino]-1,3-thiazol-4-(5H)-one
-
inhibitor for isozyme 11beta-HSD1, but not for isozyme 11beta-HSD2
(1-[2-oxo-2-[(pyridin-3-ylmethyl)amino]ethyl]cyclopentyl)acetic acid
-
11% inhibition at 0.001 mM
(1-[2-[(2,4-dichlorobenzyl)amino]-2-oxoethyl]cyclopentyl)acetic acid
-
27% inhibition at 0.001 mM
(1-[2-[(2-chloro-4-fluorobenzyl)amino]-2-oxoethyl]cyclopentyl)acetic acid
-
-
(1-[2-[(2-chlorobenzyl)amino]-2-oxoethyl]cyclopentyl)acetic acid
-
22% inhibition at 0.001 mM
(1-[2-[(4-methoxypyridin-3-yl)amino]-2-oxoethyl]cyclopentyl)acetic acid
-
7% inhibition at 0.001 mM
(1-[2-[(cyclohexylmethyl)amino]-2-oxoethyl]cyclopentyl)acetic acid
-
7% inhibition at 0.001 mM
(11beta)-11-hydroxyallopregnanolone
-
-
(11beta)-11-hydroxyprogesterone
-
-
(1E,4E)-1,5-bis(thiophen-2-yl) penta-1,4-dien-3-one
(1r,4s)-4-[[5-(cyclopropylamino)-3,3-dimethyl-5-oxopentanoyl]amino]tricyclo[3.3.1.13,7]decane-1-carboxylic acid
-
-
(1S,2R,3S,5R,6R)-4-methylidene-1-([(1S,4aS,8aS)-2,5,5,8a-tetramethyl-1,4,4a,5,6,7,8,8a-octahydronaphthalen-1-yl]methyl)-7-oxabicyclo[4.1.0]heptane-2,3,5-triol
(1S,2R,5R,6R)-4-(hydroxymethyl)-1-([(1S,4aR,6S,8aR)-6-hydroxy-2,5,5,8a-tetramethyl-1,4,4a,5,6,7,8,8a-octahydronaphthalen-1-yl]methyl)-7-oxabicyclo[4.1.0]hept-3-ene-2,5-diol
(1S,2R,5R,6R)-4-(hydroxymethyl)-1-([(1S,4aS,8aS)-2,5,5,8a-tetramethyl-1,4,4a,5,6,7,8,8a-octahydronaphthalen-1-yl]methyl)-7-oxabicyclo[4.1.0]hept-3-ene-2,5-diol
(1S,3R,4R,7S)-4-[[2-(4-methoxyphenoxy)-2-methylpropanoyl]amino]tricyclo[3.3.1.13,7]decane-1-carboxamide
(2-benzyl-4-hydroxy-1,1-dioxido-2H-1,2-benzothiazin-3-yl)(phenyl)methanone
-
-
(2alpha,3beta,5xi,6beta,9xi,18xi)-2,3,6,23-tetrahydroxyurs-12-en-28-oate
-
-
(2alpha,3beta,5xi,9xi,18xi)-2,3,23-trihydroxyurs-12-en-28-oate
-
-
(2E,4S)-4-hydroxy-5-[(1S,5S,6S)-6-(hydroxymethyl)-2-methylidenebicyclo[3.1.1]hept-6-yl]-2-methylpent-2-enoic acid
(2R)-1-(2-chloro-4-(2-methoxyethoxy)phenylsulfonyl)-4-(4-fluoro-2-(trifluoromethyl)phenyl)-2-methylpiperazine
(2R)-1-(2-chloro-4-(difluoromethoxy)phenylsulfonyl)-4-(4-fluoro-2-(trifluoromethyl)phenyl)-2-methylpiperazine
(2R)-1-(2-chloro-4-ethoxyphenylsulfonyl)-4-(4-fluoro-2-(trifluoromethyl)phenyl)-2-methylpiperazine
(2R)-1-(3-chloro-4-(4-(4-fluoro-2-(trifluoromethyl)phenyl)-2-methylpiperazin-1-ylsulfonyl)phenyl)piperidine-4-carboxamide
(2R)-1-(3-chloro-4-(4-(4-fluoro-2-(trifluoromethyl)phenyl)-2-methylpiperazin-1-ylsulfonyl)phenyl)piperidine-4-carboxylic acid
(2R)-1-(3-chloro-4-([4-(4-fluoro-2-(trifluoromethyl)-phenyl)-2-methylpiperazin-1-yl]sulfonyl)phenyl)piperidin-4-ol
(2R)-1-(4-bromo-2-chlorophenylsulfonyl)-4-(4-fluoro-2-(trifluoromethyl)phenyl)-2-methylpiperazine
(2R)-1-(4-bromophenylsulfonyl)-4-(4-fluoro-2-(trifluoromethyl)-phenyl)-2-methylpiperazine
(2R)-1-(4-tert-butoxy-2-chlorophenylsulfonyl)-4-(4-fluoro-2-(trifluoromethyl)phenyl)-2-methylpiperazine
(2R)-1-([2-chloro-4-[(3S)-3-methylpiperazin-1-yl]phenyl]sulfonyl)-4-[4-fluoro-2-(trifluoromethyl)phenyl]-2-methylpiperazine
(2R)-1-[(2-chloro-4-piperidin-1-ylphenyl)sulfonyl]-4-[4-fluoro-2-(trifluoromethyl)phenyl]-2-methylpiperazine
(2R)-1-[(2-chloro-4-pyrrolidin-1-ylphenyl)sulfonyl]-4-[4-fluoro-2-(trifluoromethyl)phenyl]-2-methylpiperazine
(2R)-1-[(4-tert-butylphenyl)sulfonyl]-2-methyl-4-(4-nitrophenyl)piperazine
-
-
(2R)-1-[(4-tert-butylphenyl)sulfonyl]-2-methyl-4-(pyridin-4-ylmethyl)piperazine
-
-
(2R)-1-[(4-tert-butylphenyl)sulfonyl]-2-methyl-4-[1-(pyridin-4-yl)ethyl]piperazine
-
-
(2R)-1-[(4-tert-butylphenyl)sulfonyl]-2-methyl-4-[2-(pyridin-4-yl)ethyl]piperazine
-
-
(2R)-1-[(4-tert-butylphenyl)sulfonyl]-2-methyl-4-[3-(pyridin-4-yl)propyl]piperazine
-
-
(2R)-1-[(4-tert-butylphenyl)sulfonyl]-2-methyl-4-[phenyl(pyridin-4-yl)methyl]piperazine
-
-
(2R)-1-[3-chloro-4-([(2R)-4-[4-fluoro-2-(trifluoromethyl)phenyl]-2-methylpiperazin-1-yl]sulfonyl)phenyl]-N,N-dimethylpiperidin-4-amine
(2R)-1-[3-chloro-4-([(2R)-4-[4-fluoro-2-(trifluoromethyl)phenyl]-2-methylpiperazin-1-yl]sulfonyl)phenyl]piperazin-2-one
(2R)-1-[[2-chloro-4-(1H-1,2,4-triazol-1-yl)phenyl]sulfonyl]-4-[4-fluoro-2-(trifluoromethyl)phenyl]-2-methylpiperazine
(2R)-1-[[2-chloro-4-(4,4-difluoropiperidin-1-yl)phenyl]sulfonyl]-4-[4-fluoro-2-(trifluoromethyl)phenyl]-2-methylpiperazine
(2R)-1-[[2-chloro-4-(4-fluoropiperidin-1-yl)phenyl]sulfonyl]-4-[4-fluoro-2-(trifluoromethyl)phenyl]-2-methylpiperazine
(2R)-1-[[2-chloro-4-(4-methylpiperazin-1-yl)phenyl]sulfonyl]-4-[4-fluoro-2-(trifluoromethyl)phenyl]-2-methylpiperazine
(2R)-1-[[4-(1,1-difluoroethyl)phenyl]sulfonyl]-2-methyl-4-[2-(pyridin-4-yl)ethyl]piperazine
-
-
(2R)-1-[[4-(1-fluoroethyl)phenyl]sulfonyl]-2-methyl-4-[2-(pyridin-4-yl)ethyl]piperazine
-
-
(2R)-1-[[4-(2-fluoropropan-2-yl)phenyl]sulfonyl]-2-methyl-4-[2-(pyridin-4-yl)ethyl]piperazine
-
-
(2R)-2-(3-chloro-4-(4-(4-fluoro-2-(trifluoromethyl)phenyl)-2-methylpiperazin-1-ylsulfonyl)phenoxy)-N,N-dimethylethanamine
(2R)-2-methyl-4-[2-(pyridin-4-yl)ethyl]-1-[[4-(1,1,1,2-tetrafluoropropan-2-yl)phenyl]sulfonyl]piperazine
-
-
(2R)-3-chloro-4-(4-(4-fluoro-2-(trifluoromethyl)phenyl)-2-methylpiperazin-1-ylsulfonyl)-N,N-dimethylaniline
(2R)-3-chloro-4-(4-(4-fluoro-2-(trifluoromethyl)phenyl)-2-methylpiperazin-1-ylsulfonyl)benzonitrile
(2R)-3-chloro-4-(4-(4-fluoro-2-(trifluoromethyl)phenyl)-2-methylpiperazin-1-ylsulfonyl)phenol
(2R)-3-chloro-4-([(2R)-4-[4-fluoro-2-(trifluoromethyl)phenyl]-2-methylpiperazin-1-yl]sulfonyl)benzamide
(2R)-4-(3-fluoro-4-(4-(4-fluoro-2-(trifluoromethyl)phenyl)-2-methylpiperazin-1-ylsulfonyl)phenyl)morpholine
(2R)-4-(4-(4-fluoro-2-(trifluoromethyl)phenyl)-2-methylpiperazin-1-ylsulfonyl)benzamide
(2R)-4-(4-(4-fluoro-2-(trifluoromethyl)phenyl)-2-methylpiperazin-1-ylsulfonyl)benzonitrile
(2R)-4-(4-fluoro-2-(trifluoromethyl)phenyl)-1-(4-methoxyphenylsulfonyl)-2-methylpiperazine
(2R)-4-(4-fluoro-2-(trifluoromethyl)phenyl)-2-methyl-1-(4-(trifluoromethoxy)-phenylsulfonyl)-piperazine
(2R)-4-[3-chloro-4-([(2R)-4-[4-fluoro-2-(trifluoromethyl)phenyl]-2-methylpiperazin-1-yl]sulfonyl)phenyl]-cis-2,6-dimethylmorpholine
(2R)-4-[3-chloro-4-([(2R)-4-[4-fluoro-2-(trifluoromethyl)phenyl]-2-methylpiperazin-1-yl]sulfonyl)phenyl]morpholine
(2R)-4-[3-chloro-4-([(2R)-4-[4-fluoro-2-(trifluoromethyl)phenyl]-2-methylpiperazin-1-yl]sulfonyl)phenyl]piperazin-2-one
(2R)-4-[3-chloro-4-([(2R)-4-[4-fluoro-2-(trifluoromethyl)phenyl]-2-methylpiperazin-1-yl]sulfonyl)phenyl]thiomorpholine-1,1-dioxide
(2R)-4-[4-fluoro-2-(trifluoromethyl)phenyl]-2-methyl-1-[(4-piperidin-1-ylphenyl)sulfonyl]piperazine
(2R)-4-[4-fluoro-2-(trifluoromethyl)phenyl]-2-methyl-1-[[4-(1H-tetrazol-5-yl)phenyl]sulfonyl]piperazine
(2R)-N-(5-hydroxytricyclo[3.3.1.13,7]dec-2-yl)-1-[(3-chloro-2-methylphenyl)sulfonyl]piperidine-2-carboxamide
(2R)-N-(tricyclo[3.3.1.13,7]dec-2-yl)-1-[(3-chloro-2-methylphenyl)sulfonyl]piperidine-2-carboxamide
(2R)-N-cycloheptyl-1-[(3-chloro-2-methylphenyl)sulfonyl]piperidine-2-carboxamide
(2R)-N-[(1R,2S,4R)-1,7,7-trimethylbicyclo[2.2.1]hept-2-yl]-1-[(3-chloro-2-methylphenyl)sulfonyl]piperidine-2-carboxamide
(2R)-N-[3-chloro-4-([4-[4-fluoro-2-(trifluoromethyl)phenyl]-piperazin-1-yl]sulfonyl)phenyl]morpholine-4-carboxamide
(2R,4aR,6aS,6bR,10S,12aS)-10-hydroxy-2,4a,6a,6b,9,9,12a-heptamethyl-1,3,4,4a,5,6,6a,6b,7,8,8a,9,10,11,12,12a,12b,14b-octadecahydropicen-13(2H)-one
-
-
(2R,4aS,6aS,12bR,14aS)-10-hydroxy-2,4a,6a,9,12b,14a-hexamethyl-11-oxo-1,2,3,4,4a,5,6,6a,11,12b,13,14,14a,14b-tetradecahydropicene-2-carboxylate
-
-
(2S)-5-(acetyloxy)-2-hydroxypentyl acetate
-
-
(3alpha,18beta,20beta)-11-oxo-3-trifluoromethylsulfonylaminoolean-12-en-29-oic acid
-
-
(3alpha,18beta,20beta)-3-(acetylamino)-11-oxo-olean-12-en-29-oicacid
-
-
(3alpha,18beta,20beta)-3-methoxyamino-11-oxo-olean-12-en-29-oic acid
-
-
(3alpha,18beta,20beta)-3-methylsulfonylamino-11-oxo-olean-12-en-29-oic acid
-
-
(3alpha,5alpha)-3,11,21-trihydroxypregn-11-en-20-one
-
-
(3beta)-3-(acetyloxy)-11-oxoolean-12-en-30-oic acid
-
-
(3beta)-3-hydroxy-11-oxoolean-12-en-30-amide
-
-
(3beta)-3-hydroxy-18,29-epoxyolean-12-ene-11,29-dione
IC50 value for isoform 11beta-HSD2 above 25 microM. Docking studies into isoforms 11beta-HSD1 and 11beta-HSD2 binding sites
(3beta)-3-hydroxyandrost-5-en-17-one
-
treatment of rats induces a shift from isoform 11beta-HSD1 to 11beta-HSD2 expression, increasing conversion from active to inactive glucocorticoids. Dehydroepiandrosterone likely modulates the transcription of 11beta-HSD2 in a phosphatidylinositol-3 kinase/Akt-dependent manner by increasing CCAAT/enhancer-binding protein beta mRNA and protein expression
(3beta)-3-[(3-carboxypropanoyl)oxy]urs-12-en-28-oic acid
IC50 value for isoform 11beta-HSD2 above 3 microM. Docking studies into isoforms 11beta-HSD1 and 11beta-HSD2 binding sites
(3beta)-30-[hydroxy(methyl)amino]-11,30-dioxoolean-12-en-3-yl acetate
IC50 value for isoform 11beta-HSD1 above 1 microM. Docking studies into isoforms 11beta-HSD1 and 11beta-HSD2 binding sites
(3beta)-N,3-dihydroxy-11-oxoolean-12-en-30-amide
-
-
(3beta,18beta,20beta)-11-oxo-3-succinylamino-olean-12-en-29-oic acid
-
-
(3beta,18beta,20beta)-11-oxo-3-trifluoromethylsulfonylaminoolean-12-en-29-oic acid
-
-
(3beta,18beta,20beta)-3,N-dihydroxy-N-methyl-11-oxo-olean-12-en-29-amide
-
-
(3beta,18beta,20beta)-3-(2-carboxy-ethylsulfonylamino)-11-oxoolean-12-en-29-oic acid
-
-
(3beta,18beta,20beta)-3-(2-methoxycarbonyl-ethylsulfonylamino)-11-oxo-olean-12-en-29-oic acid
-
-
(3beta,18beta,20beta)-3-(acetylamino)-11-oxo-olean-12-en-29-oic acid
-
-
(3beta,18beta,20beta)-3-acetoxy-N-hydroxy-11-oxo-olean-12-en-29-amide
-
-
(3beta,18beta,20beta)-3-acetoxy-N-methoxy-11-oxo-olean-12-en-29-amide
-
-
(3beta,18beta,20beta)-3-acetoxy-N-methyl-N-hydroxy-11-oxoolean-12-en-29-amide
-
-
(3beta,18beta,20beta)-3-acetylamino-N-hydroxy-N-methyl-11-oxoolean-12-en-29-amide
-
-
(3beta,18beta,20beta)-3-amino-11-oxoolean-12-en-29-oic acid, diphenylmethyl ester
-
-
(3beta,18beta,20beta)-3-hydroxy-N-methoxy-11-oxo-olean-12-en-29-amide
-
-
(3beta,18beta,20beta)-3-methoxyamino-11-oxo-olean-12-en-29-oic acid
-
-
(3beta,18beta,20beta)-3-methylsulfonylamino-11-oxo-olean-12-en-29-oic acid
-
-
(3beta,18beta,20beta)-N-hydroxy-N-methyl-11-oxo-3-[(trifluoromethylsulfonyl)amino]-olean-12-en-29-amide
-
-
(3beta,18beta,20beta)-N-hydroxy-N-methyl-3-methoxyamino-11-oxo-olean-12-en-29-amide
-
-
(3beta,5xi,18xi)-oleana-9(11),12-diene-3,30-diol
-
-
(3beta,5xi,9xi)-oleana-11,13(18)-diene-3,30-diol
-
-
(3beta,5xi,9xi,18xi)-3,30-dihydroxyolean-12-en-11-one
-
-
(3beta,5xi,9xi,18xi)-3-(acetyloxy)-11-oxours-12-en-24-oate
-
-
(3beta,5xi,9xi,18xi)-3-(acetyloxy)urs-12-en-24-oate
-
-
(3beta,5xi,9xi,18xi)-3-hydroxy-11-oxoolean-12-en-30-al
-
-
(3beta,5xi,9xi,18xi)-3-hydroxy-11-oxoolean-12-en-30-oate
-
-
(3beta,5xi,9xi,18xi)-3-hydroxy-11-oxours-12-en-28-oate
-
-
(3beta,5xi,9xi,18xi)-3-hydroxyolean-12-en-28-oate
-
-
(3E)-3-(methoxyimino)-11-oxoolean-12-en-30-oic acid
-
-
(3E)-3-[[(4-bromo-3-methylphenoxy)acetyl]hydrazono]-N-tricyclo[3.3.1.13,7]dec-1-ylbutanamide
(3R,4R,7S)-4-[[(1-[4-[5-(trifluoromethyl)pyridin-2-yl]piperazin-1-yl]cyclopropyl)carbonyl]amino]tricyclo[3.3.1.13,7]decane-1-carboxamide
(3R,4R,7S)-4-[[(1-[4-[5-(trifluoromethyl)pyridin-2-yl]piperazin-1-yl]cyclopropyl)carbonyl]amino]tricyclo[3.3.1.13,7]decane-1-carboxylic acid
(3R,4R,7S)-4-[[2-(4-chlorophenoxy)-2-methylpropanoyl]amino]tricyclo[3.3.1.13,7]decane-1-carboxamide
(3S,4aR,6aR,6bS,8aS,11S,12aR,14aR,14bS)-4,4,6a,6b,8a,11,14b-heptamethyl-11-[(methylsulfonyl)amino]-14-oxo-1,2,3,4,4a,5,6,6a,6b,7,8,8a,9,10,11,12,12a,14,14a,14b-icosahydropicen-3-yl acetate
IC50 value for isoform 11beta-HSD1 above 40 microM. Docking studies into isoforms 11beta-HSD1 and 11beta-HSD2 binding sites
(4-hydroxy-1,1-dioxido-2H-1,2-benzothiazin-3-yl)(phenyl)methanone
-
-
(4-hydroxy-2-methyl-1,1-dioxido-2H-1,2-benzothiazin-3-yl)(phenyl)methanone
-
-
(4aS,5R,8aR)-5,6-bis(hydroxymethyl)-1,1,4a-trimethyl-1,2,3,4,4a,5,8,8a-octahydronaphthalen-2-ol
(4aS,5S,8aR)-5-(hydroxymethyl)-1,1,4a,6-tetramethyl-1,2,3,4,4a,5,8,8a-octahydronaphthalen-2-ol
(4aS,5S,8aR)-5-(hydroxymethyl)-1,1,4a,6-tetramethyl-3,4,4a,5,8,8a-hexahydronaphthalen-2(1H)-one
(5R)-2-[[(1S)-1-(2-fluorophenyl)ethyl]amino]-5-methyl-5-(trifluoromethyl)-1,3-thiazol-4(5H)-one
(5xi,9xi,18xi)-3,11-dioxoolean-12-en-30-al
-
-
(6-[[(3-chloro-2-methylphenyl)sulfonyl]amino]pyridin-2-yl)acetic acid
-
-
(6S)-6-(4-fluorophenyl)-6-(2-hydroxyethyl)-3-[1-(2',4'-difluorobiphenyl-4-yl)ethyl]-1,3-oxazinan-2-one
-
displays more than 1000fold selectivity for isoform 11beta-HSD1 over three related hydroxysteroid dehydrogenases, three CYP isozymes, hERG, and three nuclear receptors. When dosed orally at 30 mg/kg to mice, compound is distributed into adipose and liver
(6S)-6-(4-fluorophenyl)-6-(2-hydroxyethyl)-3-[1-(4'-fluorobiphenyl-4-yl)ethyl]-1,3-oxazinan-2-one
-
-
(R)-2-((1R,2R,4S)-bicyclo[2.2.1]heptan-2-ylamino)-5-isopropyl-5-methylthiazol-4(5H)-one
-
-
(R)-2-((1R,2R,4S)-bicyclo[2.2.1]heptan-2-ylamino)-5-isopropylthiazol-4(5H)-one
-
-
(R)-2-((1S,2S,4R)-bicyclo[2.2.1]heptan-2-ylamino)-5-isopropyl-5-methylthiazol-4(5H)-one
-
-
(R)-2-((1S,2S,4R)-bicyclo[2.2.1]heptan-2-ylamino)-5-isopropylthiazol-4(5H)-one
-
-
(S)-2-((1R,2R,4S)-bicyclo[2.2.1]heptan-2-ylamino)-5-isopropyl-5-methylthiazol-4(5H)-one
-
-
(S)-2-((1R,2R,4S)-bicyclo[2.2.1]heptan-2-ylamino)-5-isopropylthiazol-4(5H)-one
-
-
(S)-2-((1S,2S,4R)-bicyclo[2.2.1]heptan-2-ylamino)-5-isopropyl-5-methylthiazol-4(5H)-one
-
-
(S)-2-((1S,2S,4R)-bicyclo[2.2.1]heptan-2-ylamino)-5-isopropylthiazol-4(5H)-one
-
-
1'-[[1-(4-chlorophenyl)cyclopropyl]carbonyl]-2,3-dihydrospiro[indene-1,3'-piperidine]
-
-
1'-[[1-(4-chlorophenyl)cyclopropyl]carbonyl]-2,3-dihydrospiro[indene-1,3'-pyrrolidine]
-
-
1'-[[1-(4-chlorophenyl)cyclopropyl]carbonyl]-3,4-dihydro-2H-spiro[naphthalene-1,3'-pyrrolidine]
-
-
1'-[[1-(4-chlorophenyl)cyclopropyl]carbonyl]spiro[indene-1,4'-piperidine]
-
-
1,1,1-trifluoro-2-(4-[[(2R)-2-methyl-4-[[1-(pyridin-3-yl)cyclobutyl]methyl]piperazin-1-yl]sulfonyl]phenyl)propan-2-ol
-
-
1,1,1-trifluoro-2-(4-[[(2R)-2-methyl-4-[[1-(pyridin-3-yl)cyclopentyl]methyl]piperazin-1-yl]sulfonyl]phenyl)propan-2-ol
-
-
1,1,1-trifluoro-2-(4-[[(2R)-2-methyl-4-[[1-(pyridin-3-yl)cyclopropyl]methyl]piperazin-1-yl]sulfonyl]phenyl)propan-2-ol
-
-
1,1,1-trifluoro-2-(4-[[(2R)-2-methyl-4-[[1-(pyridin-4-yl)cyclobutyl]methyl]piperazin-1-yl]sulfonyl]phenyl)propan-2-ol
-
-
1,1,1-trifluoro-2-(4-[[(2R)-2-methyl-4-[[1-(pyridin-4-yl)cyclopentyl]methyl]piperazin-1-yl]sulfonyl]phenyl)propan-2-ol
-
-
1,1,1-trifluoro-2-(4-[[(2R)-2-methyl-4-[[1-(pyridin-4-yl)cyclopropyl]methyl]piperazin-1-yl]sulfonyl]phenyl)propan-2-ol
-
-
1,1,1-trifluoro-2-[4-([(2R)-2-methyl-4-[2-(pyridin-2-yl)ethyl]piperazin-1-yl]sulfonyl)phenyl]propan-2-ol
-
-
1,1,1-trifluoro-2-[4-([(2R)-2-methyl-4-[2-(pyridin-3-yl)ethyl]piperazin-1-yl]sulfonyl)phenyl]propan-2-ol
-
-
1,1,1-trifluoro-2-[4-([(2R)-2-methyl-4-[2-(pyridin-4-yl)ethyl]piperazin-1-yl]sulfonyl)phenyl]propan-2-ol
-
-
1-(((R)-3-methyl-4-(4-((S)-1,1,1-trifluoro-2-hydroxypropan-2-yl)phenylsulfonyl)-piperazin-1-yl)methyl)-cyclopropanecarboxamide
-
substrate competitive inhibitor, specific for 11beta-hydroxysteroid dehydrogenase type 1
1-(2,4-dichlorophenyl)-2-(2-methylbenzo[d]thiazol-5-ylamino)-ethanone
-
-
1-(3,4-dimethoxyphenyl)-2-[(1-phenyl-1H-tetrazol-5-yl)sulfanyl]ethanone
-
poor stability in liver microsomes
1-(3-chloro-4-[5-[1-(4-chlorophenyl)cyclobutyl]-4-methyl-4H-1,2,4-triazol-3-yl]phenyl)-2-methyl-1H-benzimidazole
1-(3-methoxyphenyl)-2-(phenylsulfonyl)ethanone
1-(4-chlorophenyl)-2-(2-methylbenzo[d]thiazol-5-ylamino)ethanone
-
-
1-(5-oxo-2,5-dihydrofuran-3-yl)urea
-
specific for isozyme 11beta-HSD1
1-adamantan-1-yl-2-(2,4-dichloro-benzylsulfanyl)ethanone
-
-
1-adamantan-1-yl-2-(2,4-dichloro-phenylmethanesulfonyl)ethanone
-
-
1-adamantan-1-yl-2-(2-chloro-benzylsulfanyl)ethanone
-
-
1-adamantan-1-yl-2-(2-chloro-phenylmethanesulfinyl)ethanone
-
-
1-adamantan-1-yl-2-(2-chloro-phenylmethanesulfonyl)ethanone
-
-
1-adamantan-1-yl-2-(2-methylbenzothiazol-5-ylamino)ethanone
-
-
1-adamantan-1-yl-2-(2-methylbenzothiazol-5-yloxy)ethanone
-
-
1-adamantan-1-yl-2-(3,4-dimethoxy-benzyloxy)ethanone
-
-
1-adamantan-1-yl-2-(3,4-dimethoxy-phenoxy)ethanone
-
-
1-adamantan-1-yl-2-(3-methylbenzylsulfanyl)ethanone
-
-
1-adamantan-1-yl-2-(3-trifluoromethyl-phenoxy)ethanone
-
-
1-adamantan-1-yl-2-(3-trifluoromethylbenzyloxy)ethanone
-
-
1-adamantan-1-yl-2-(4-chloro-benzenesulfinyl)ethanone
-
-
1-adamantan-1-yl-2-(4-chloro-benzenesulfonyl)ethanone
-
-
1-adamantan-1-yl-2-(4-chloro-benzyloxy)ethanone
-
-
1-adamantan-1-yl-2-(4-chloro-benzylsulfanyl)ethanone
-
-
1-adamantan-1-yl-2-(4-chloro-phenoxy)ethanone
-
-
1-adamantan-1-yl-2-(4-chloro-phenylmethanesulfinyl)ethanone
-
-
1-adamantan-1-yl-2-(4-chloro-phenylmethanesulfonyl)ethanone
-
-
1-adamantan-1-yl-2-(4-chloro-phenylsulfanyl)ethanone
-
-
1-adamantan-1-yl-2-(4-methoxy-benzyloxy)ethanone
-
-
1-adamantan-1-yl-2-(4-methylbenzyloxy)ethanone
-
-
1-adamantan-1-yl-2-(4-tert-butyl-phenylmethanesulfinyl)ethanone
-
-
1-adamantan-1-yl-2-(4-tert-butyl-phenylmethanesulfonyl)ethanone
-
-
1-adamantan-1-yl-2-(4-tert-butylbenzylsulfanyl)ethanone
-
-
1-adamantan-1-yl-2-(4-trifluoromethyl-phenoxy)ethanone
-
-
1-adamantan-1-yl-2-(4-trifluoromethylbenzyloxy)ethanone
-
-
1-adamantan-1-yl-2-(biphenyl-4-ylmethoxy)ethanone
-
-
1-adamantan-1-yl-2-(biphenyl-4-yloxy)ethanone
-
-
1-adamantan-1-yl-2-(toluene-4-sulfinyl)ethanone
-
-
1-adamantan-1-yl-2-(toluene-4-sulfonyl)ethanone
-
-
1-adamantan-1-yl-2-m-tolylmethanesulfonyl-ethanone
-
-
1-adamantan-1-yl-2-p-tolyloxy-ethanone
-
-
1-adamantan-1-yl-2-p-tolylsulfanyl-ethanone
-
-
1-methyl-4-(4-methyl-5-phenyl-4H-1,2,4-triazol-3-yl)-1H-indole
1-methyl-4-[4-methyl-5-[2-(trifluoromethyl)phenyl]-4H-1,2,4-triazol-3-yl]-1H-indole
1-methyl-5-(4-methyl-5-phenyl-4H-1,2,4-triazol-3-yl)-1H-indole
1-phenyl-2-[(1-phenyl-1H-tetrazol-5-yl)sulfanyl]ethanone
-
poor stability in liver microsomes
1-piperidinecarboxylic acid
-
-
1-[(1R,2R,7S)-5-[(aminooxy)methyl]tricyclo[3.3.1.13,7]dec-2-yl]-3,3-dimethyl-4-([[5-(1H-1,2,4-triazol-1-yl)pyridin-2-yl]oxy]methyl)pyrrolidin-2-one
1-[(2,4-dichlorophenyl)sulfonyl]-4-[3-(trifluoromethyl)pyridin-2-yl]piperazine
-
-
1-[(2-chlorobenzyl)oxy]-7-fluoro-3-hydroxyisoquinoline-4-carbonitrile
1-[(2-chlorobenzyl)sulfanyl]-3-hydroxy-5,6,7,8-tetrahydroisoquinoline-4-carbonitrile
1-[(2-chlorobenzyl)sulfanyl]-7-fluoro-3-hydroxyisoquinoline-4-carbonitrile
1-[(2-naphthylphenyl)sulfonyl]-4-[3-(trifluoromethyl)pyridin-2-yl]piperazine
-
-
1-[(3-chloro-2-methylcyclohexyl)sulfonyl]-N-[(+)-bornyl]piperidine-3-carboxamide
1-[(3-chloro-2-methylcyclohexyl)sulfonyl]-N-[(+)-isopinocampheyl]piperidine-3-carboxamide
1-[(4-methylphenyl)sulfonyl]-4-[3-(trifluoromethyl)pyridin-2-yl]piperazine
-
-
1-[(4-nitrophenyl)sulfonyl]-4-[3-(trifluoromethyl)pyridin-2-yl]piperazine
-
-
1-[(4-tert-butylphenyl)sulfonyl]-(2R)-2-methyl-4-(4-nitrophenyl)piperazine
-
-
1-[(4-tert-butylphenyl)sulfonyl]-(2R)-2-methyl-4-[3-(trifluoromethyl)pyridin-2-yl]piperazine
-
-
1-[(4-tert-butylphenyl)sulfonyl]-(2S)-2-methyl-4-[3-(trifluoromethyl)pyridin-2-yl]piperazine
-
-
1-[(4-tert-butylphenyl)sulfonyl]-2-methyl-4-[3-(trifluoromethyl)pyridin-2-yl]piperazine
-
-
1-[(4-tert-butylphenyl)sulfonyl]-4-(4-nitrophenyl)piperazine
-
-
1-[(4-tert-butylphenyl)sulfonyl]-4-(5-nitropyridin-2-yl)piperazine
-
-
1-[(4-tert-butylphenyl)sulfonyl]-4-[3-(trifluoromethyl)pyridin-2-yl]piperazine
-
-
1-[(4-tert-butylphenyl)sulfonyl]-5-[3-(trifluoromethyl)pyridin-2-yl]-1,5-diazocane
-
-
1-[1-(3,4-dimethylbenzoyl)piperidin-4-yl]-1,3-dihydro-2H-benzimidazol-2-one
-
-
1-[1-(3-methoxy-4-methylbenzoyl)piperidin-4-yl]-1,3-dihydro-2H-benzimidazol-2-one
-
-
1-[1-[(3,4-dimethylphenyl)carbonyl]piperidin-4-yl]-1,3-dihydro-2H-benzimidazol-2-one
1-[1-[(3-amino-4-methoxyphenyl)carbonyl]piperidin-4-yl]-1,3-dihydro-2H-benzimidazol-2-one
-
-
1-[1-[(3-methoxyphenyl)carbonyl]piperidin-4-yl]-1,3-dihydro-2H-benzimidazol-2-one
1-[1-[(4-methoxy-3-methylphenyl)carbonyl]piperidin-4-yl]-1,3-dihydro-2H-benzimidazol-2-one
-
-
1-[4-([(2R)-2-methyl-4-[2-(pyridin-4-yl)ethyl]piperazin-1-yl]sulfonyl)phenyl]ethanol
-
-
1-[[(3R)-3-methyl-4-([4-[(2R)-1,1,1-trifluoro-2-hydroxypropan-2-yl]phenyl]sulfonyl)piperazin-1-yl]methyl]cyclopropanecarboxamide
-
-
1-[[(3R)-3-methyl-4-([4-[(2S)-1,1,1-trifluoro-2-hydroxypropan-2-yl]phenyl]sulfonyl)piperazin-1-yl]methyl]cyclopropanecarboxamide
-
-
1-[[(3R)-3-methyl-4-[[4-(1,1,1-trifluoro-2-hydroxypropan-2-yl)phenyl]sulfonyl]piperazin-1-yl]methyl]cyclobutanecarboxamide
-
-
1-[[(3R)-3-methyl-4-[[4-(1,1,1-trifluoro-2-hydroxypropan-2-yl)phenyl]sulfonyl]piperazin-1-yl]methyl]cyclopropanecarboxamide
-
-
1-[[6-(4-nitrophenyl)pyridin-2-yl]carbonyl]decahydroquinoline
-
-
11-dehydrocortisterone
-
-
11-deoxycorticosterone
11-ketotestosterone
-
-
11-oxo-3alpha,5alpha-tetrahydrotestosterone
-
-
11-oxo-3beta,5alpha-tetrathydrotestosterone
-
-
11-oxo-allopregnanolone
11-oxo-androstenedione
-
-
11-oxo-progesterone
11-oxo-testosterone
11-oxoandrosterone
-
0.0021 mM, 50% inhibition of oxido-reductase reaction
11-Oxoprogesterone
-
0.0095 mM, 50% inhibition of oxido-reductase reaction
11-oxotestosterone
-
0.018 mM, 50% inhibition of oxido-reductase reaction
11beta,17,21-trihydroxy-pregn-4-ene-3,20-dione
11beta,21-dihydroxypregn-4-en-3,20-dione
-
potent inhibition of cortisol oxidation
11beta-hydroxy-allopregnanolone
-
-
11beta-hydroxy-androstanediol
-
-
11beta-hydroxy-testosterone
-
-
11beta-hydroxyandrostanediol
-
-
11beta-hydroxyandrostenedione
-
-
-
11beta-hydroxyandrosterone
-
0.07 mM, 50% inhibition of dehydrogenase reaction
11beta-hydroxydehydroepiandrosterone
-
0.003 mM, 50% inhibition of dehydrogenase reaction
11beta-hydroxyprogesterone
11beta-hydroxytestosterone
17beta-estradiol
17beta-estradiol-3-acetate
-
-
18alpha-glycyrrhetinic acid
-
selective inhibition of 11beta-HSD1, does not inhibit 11beta-HSD2 at concentrations up to 0.02 mM
18beta-glycyrrhetinic acid
2'-hydroxyflavanone
2,3-dihydro-4H-1,4-benzoxazin-4-yl[3-(1H-pyrazol-4-yl)pyrrolidin-1-yl]methanone
2,4-dichloro-N-[4-[(4aR,8aS)-octahydroquinolin-1(2H)-ylcarbonyl]naphthalen-1-yl]benzamide
2,4-dichloro-N-[4-[(4aR,8aS)-octahydroquinolin-1(2H)-ylcarbonyl]phenyl]benzamide
2,5-dichloro-N-(2-methyl-1,3-benzothiazol-5-yl)benzenesulfonamide
-
-
2,6-dichloro-4-[(5,7,7-trimethyl-2-azabicyclo[3.2.1]oct-2-yl)carbonyl]aniline
2-(1-adamantylamino)-1-thia-3-azaspiro[4.4]non-2-en-4-one
-
inhibitor for isozyme 11beta-HSD1, but not for isozyme 11beta-HSD2
2-(1-adamantylamino)-5,5-diethyl-1,3-thiazol-4-(5H)-one
-
inhibitor for isozyme 11beta-HSD1, but not for isozyme 11beta-HSD2
2-(1-[2-oxo-2-[(pyridin-2-ylmethyl)amino]ethyl]cyclopentyl)-N-tricyclo[3.3.1.13,7]dec-2-ylacetamide
-
-
2-(1-[2-[(2-methoxyphenyl)amino]-2-oxoethyl]cyclopentyl)-N-tricyclo[3.3.1.13,7]dec-2-ylacetamide
-
-
2-(1-[2-[(2-methylpropyl)amino]-2-oxoethyl]cyclopentyl)-N-tricyclo[3.3.1.13,7]dec-2-ylacetamide
-
-
2-(1-[2-[(4-fluorobenzyl)amino]-2-oxoethyl]cyclopentyl)-N-tricyclo[3.3.1.13,7]dec-2-ylacetamide
-
-
2-(1-[2-[(4-fluorophenyl)amino]-2-oxoethyl]cyclopentyl)-N-tricyclo[3.3.1.13,7]dec-2-ylacetamide
-
-
2-(1-[2-[(4-methoxyphenyl)amino]-2-oxoethyl]cyclopentyl)-N-tricyclo[3.3.1.13,7]dec-2-ylacetamide
-
-
2-(2,4-dibromophenoxy)-N-[3-(1-hydroxyethyl)phenyl]propanamide
2-(2-chloro-4-fluorophenoxy)-2-methyl-N-[(1R,2R,7S)-5-(methylsulfonyl)tricyclo[3.3.1.13,7]dec-2-yl]propanamide
2-(2-chloro-4-fluorophenoxy)-2-methyl-N-[(1R,2R,7S)-5-sulfamoyltricyclo[3.3.1.13,7]dec-2-yl]propanamide
2-(2-chlorophenyl)-6-[(3,3-dimethylpiperidin-1-yl)carbonyl]pyridine
-
-
2-(2-hydroxyphenyl)-2,3-dihydro-4H-chromen-4-one
-
-
2-(2-methyl-2-phenylpropanoyl)-2-azaspiro[4.5]decane
-
-
2-(2-[[(3-chloro-2-methylphenyl)sulfonyl]amino]-1,3-thiazol-4-yl)-N,N-diethylacetamide
2-(3-benzoyl-4-hydroxy-1,1-dioxido-2H-1,2-benzothiazin-2-yl)-1-(4-nitrophenyl)ethanone
-
-
2-(3-benzoyl-4-hydroxy-1,1-dioxido-2H-1,2-benzothiazin-2-yl)-1-(biphenyl-4-yl)ethanone
-
-
2-(3-benzoyl-4-hydroxy-1,1-dioxido-2H-1,2-benzothiazin-2-yl)-1-phenylethanone
2-(3-chloro-4-[5-[1-(4-chlorophenyl)cyclobutyl]-4-methyl-4H-1,2,4-triazol-3-yl]phenyl)pyridine
2-(3-noradamantylamino)-1-thia-3-azaspiro[4.4]non-2-en-4-one
-
inhibitor for isozyme 11beta-HSD1, but not for isozyme 11beta-HSD2
2-(4-chlorophenoxy)-N-[(1R,2R,7S)-5-(hydroxycarbamimidoyl)tricyclo[3.3.1.13,7]dec-2-yl]-2-methylpropanamide
2-(4-chlorophenyl)-6-[(3,3-dimethylpiperidin-1-yl)carbonyl]pyridine
-
-
2-(4-hydroxyphenyl)-2,3-dihydro-4H-chromen-4-one
-
-
2-(4-methylphenyl)-2-oxoethyl 2-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)-3-phenylpropanoate
-
-
2-(4-[1-[5-(4-chlorophenyl)-4-methyl-4H-1,2,4-triazol-3-yl]cyclobutyl]phenyl)pyridine
-
-
2-(6-[[(3-chloro-2-methylphenyl)sulfonyl]amino]pyridin-2-yl)-N,N-diethylacetamide
-
-
2-(adamantan-1-yl)-N-methyl-N-(thiophen-3-ylmethyl)acetamide
-
-
2-(bicyclo[2.2.1]hept-2-ylamino)-5-(propan-2-yl)-1,3-thiazol-4(5H)-one
-
-
2-(cycloheptylamino)-5-methyl-5-(1-methylethyl)-1,3-thiazol-4(5H)-one
2-(cyclooctylamino)-1-thia-3-azaspiro[4.4]non-2-en-4-one
-
inhibitor for isozyme 11beta-HSD1, but not for isozyme 11beta-HSD2
2-(cyclooctylamino)-5,5-diethyl-1,3-thiazol-4-(5H)-one
-
inhibitor for isozyme 11beta-HSD1, but not for isozyme 11beta-HSD2
2-adamantan-1-yl-N-methyl-N-thiophen-2-ylmethyl-acetamide
-
-
2-bis(p-hydroxyphenyl)-1,1,1-trichloroethane
2-bromo-N-[2-([2-oxo-2-[(2-phenylethyl)amino]ethyl]sulfanyl)-2,3-dihydro-1,3-benzothiazol-6-yl]benzamide
-
-
2-chloro-N-(4-[[(2R,6S)-2,6-dimethylmorpholin-4-yl]carbonyl]benzyl)benzenesulfonamide
2-oxopentane-1,5-diyl diacetate
2-[(1-phenylcyclopropyl)carbonyl]-2-azaspiro[4.5]decane
-
-
2-[(1-pyridin-2-ylcyclopropyl)carbonyl]-2-azaspiro[4.5]decane
-
-
2-[(1-pyridin-4-ylcyclopropyl)carbonyl]-2-azaspiro[4.5]decane
-
-
2-[(1S,2S,4R)-bicyclo[2.2.1]hept-2-ylamino]-5-methyl-5-(propan-2-yl)-1,3-thiazol-4(5H)-one
-
-
2-[(2-chlorobenzyl)sulfanyl]-4-hydroxy-6-phenylpyrimidine-5-carbonitrile
2-[(3,3-dimethylpiperidin-1-yl)carbonyl]-6-(3-fluoro-4-methylphenyl)pyridine
-
-